Suppr超能文献

预防性乳房切除术的 BRCA1/2 或其他高外显率致病性变异携带者隐匿性乳腺癌的发生率:何时需要进行前哨淋巴结活检?

Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?

机构信息

Department of Surgery, McGill University Medical School, Montreal, QC, Canada.

Jewish General Hospital Stroll Cancer Prevention Centre, Montreal, QC, Canada.

出版信息

Ann Surg Oncol. 2022 Oct;29(11):6660-6668. doi: 10.1245/s10434-022-11916-3. Epub 2022 May 26.

Abstract

BACKGROUND

This study sought to determine the likelihood of occult malignancy during risk-reducing mastectomy in high-penetrance pathogenic variant carriers to help refine axillary staging recommendations.

METHODS

The authors performed a retrospective cohort study analyzing all female carriers of pathogenic variants in BRCA1/2, PALB2 or other genes who underwent prophylactic surgery at their institution between 2006 and 2021. Occult breast cancer was defined as the unanticipated presence of in situ or invasive malignancy on pathologic evaluation of prophylactic mastectomy specimens.

RESULTS

Of 523 women, 243 carriers met the inclusion criteria for the study including 124 BRCA1 (51.0%), 108 BRCA2 (44.4%), and 11 PALB2, TP53, CDH1, or PTEN (4.6%) carriers. The median age was 44 years (interquartile range, 37-52 years). Overall, 128 women (52.7%) underwent bilateral prophylactic mastectomies, and 115 (47.3%) underwent contralateral prophylactic mastectomy. In the 371 mastectomies performed, 16 (4.3%) occult malignancies were diagnosed. Most of the occult malignancies were ductal carcinoma in situ (13 mastectomies, 3.5%), whereas 3 mastectomies (0.8%) contained invasive breast cancer. If Breast Imaging Reporting and Data System (BIRADS) 1-2 or BIRADS 3 findings were reported on preoperative magnetic resonance imaging (MRI), the rate of occult malignancy decreased to 3.0 and 2.8%, respectively, per mastectomy. The patient-level factors associated with a likelihood of occult breast cancer greater than 10% included a history of prior breast cancer, age exceeding 60 years, and BIRADS 4 findings on preoperative imaging.

CONCLUSIONS

Occult invasive malignancy was detected in less than 1% of the risk-reducing mastectomies performed for women with BRCA1/2 or PALB2 pathogenic variants. Sentinel lymph node biopsy can be safely avoided when BIRADS 1-3 findings are reported on preoperative MRI.

摘要

背景

本研究旨在确定高外显率致病性变异携带者在接受降低风险的乳房切除术时发生隐匿性恶性肿瘤的可能性,以帮助完善腋窝分期建议。

方法

作者进行了一项回顾性队列研究,分析了 2006 年至 2021 年间在本机构接受预防性手术的 BRCA1/2、PALB2 或其他基因致病性变异携带者的所有女性。隐匿性乳腺癌定义为预防性乳房切除术标本病理评估时意外出现原位或浸润性恶性肿瘤。

结果

在 523 名女性中,有 243 名符合研究纳入标准的携带者,包括 124 名 BRCA1(51.0%)、108 名 BRCA2(44.4%)和 11 名 PALB2、TP53、CDH1 或 PTEN(4.6%)携带者。中位年龄为 44 岁(四分位距 37-52 岁)。总体而言,128 名女性(52.7%)接受了双侧预防性乳房切除术,115 名女性(47.3%)接受了对侧预防性乳房切除术。在 371 例乳房切除术中,诊断出 16 例(4.3%)隐匿性恶性肿瘤。大多数隐匿性恶性肿瘤为导管原位癌(13 例乳房切除术,3.5%),3 例乳房切除术(0.8%)包含浸润性乳腺癌。如果术前磁共振成像(MRI)报告乳腺影像报告和数据系统(BIRADS)1-2 或 BIRADS 3 结果,每例乳房切除术的隐匿性恶性肿瘤发生率分别降至 3.0%和 2.8%。与隐匿性乳腺癌可能性大于 10%相关的患者因素包括既往乳腺癌史、年龄超过 60 岁以及术前影像学检查发现 BIRADS 4 结果。

结论

在接受 BRCA1/2 或 PALB2 致病性变异携带者行降低风险的乳房切除术时,不到 1%的患者发现隐匿性浸润性恶性肿瘤。当术前 MRI 报告 BIRADS 1-3 结果时,可以安全避免前哨淋巴结活检。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验